



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** February 5, 2010

**To:** Primary Clinical Research Associates

**From:** Alicia Elsing  
Research Protocol Specialist III

**Re:** N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age  $\geq$ 70 yrs) with Good Performance Status (PS  $<$ 2)

The status change notice to temporarily close the study on October 30, 2009 has been revised. The actual temporary closure date was November 2, 2009. A revised status change notice has been posted to the web site. We apologize for any inconvenience this may have caused.

**NOTE:** This revised status change notice is being distributed as a FYI only as the study re-opened to patient accrual December 22, 2009.

If you have any questions, please feel free to contact me at [elsing.alicia@mayo.edu](mailto:elsing.alicia@mayo.edu) or 507-538-3893.

Enclosure

North Central Cancer Treatment Group

N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age  $\geq 70$  yrs) with Good Performance Status (PS  $< 2$ )

Revised Status Change – November 2, 2009

**NOTICE OF STATUS CHANGE**

This study was actually temporarily suspended to patient accrual effective Monday, November 2, 2009.

**Please retain this notice with the protocol.**